Simon Dumesnil
Director · Pasithea Therapeutics Corp.
- 2025
- May 5, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Simon Dumesnil files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Lawrence Steinman - $100K in KTTA purchases and sales in the last 12 months
- Coastlands Capital LP - $53K in KTTA purchases and sales in the last 12 months
- Tiago Marques - $25K in KTTA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Simon Dumesnil?
Simon Dumesnil is a corporate insider, tracked as Director of Pasithea Therapeutics Corp. (KTTA). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Simon Dumesnil last file a Form 4?
The most recent primary Form 4 on record is dated 5 May 2026, one of 3 filings going back to 2025.
Has Simon Dumesnil been buying or selling stock?
Recorded transactions: 1 open-market purchase ($25K) and 0 open-market sales across all tracked filings.
